Evidence map›Paper›PMID 42072630›Full record

ArticleBiomolecules2026

Annexin A1 and Dexamethasone Treatment in Hospitalized COVID-19 Patients: Impact on Disease Recovery and Evidence for an Interplay Between Proresolving Mediators.

Carolina Silva-Pereira, Marta Reina-Couto, Patrícia Pereira-Terra, Luísa Teixeira-Santos, Sandra Martins, Dora Pinho, Miguel Luz Soares, Cláudia Camila Dias, António Sarmento, Margarida Tavares and 6 more

Abstract read
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Carolina Silva-PereiraRISE-Health, Departamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
Marta Reina-CoutoRISE-Health, Departamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
Patrícia Pereira-TerraDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 3, 4200-450 Porto, Portugal.
Luísa Teixeira-SantosDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 3, 4200-450 Porto, Portugal.ORCID 0000-0001-7729-9010
Sandra MartinsUnidade de Investigação em Epidemiologia (EPIUnit), Instituto de Saúde Pública da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal.ORCID 0000-0001-6813-314X
Dora PinhoRISE-Health, Departamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.ORCID 0000-0001-6965-8597
Miguel Luz SoaresDepartamento de Biomedicina-Unidade de Biologia Experimental, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 4, 4200-450 Porto, Portugal.ORCID 0000-0002-1812-6117
Cláudia Camila DiasRISE-Health, Departamento de Medicina da Comunidade, Informação e Decisão em Saúde (MEDCIDS), Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.ORCID 0000-0001-9356-3272
António SarmentoServiço de Doenças Infecciosas, Centro Hospitalar e Universitário de São João (CHUSJ), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
Margarida TavaresUnidade de Investigação em Epidemiologia (EPIUnit), Instituto de Saúde Pública da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal.ORCID 0000-0003-4518-2197
João Tiago GuimarãesUnidade de Investigação em Epidemiologia (EPIUnit), Instituto de Saúde Pública da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal.ORCID 0000-0003-4836-6311
José-Artur PaivaServiço de Medicina Intensiva, Centro Hospitalar e Universitário de São João (CHUSJ), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.ORCID 0000-0003-4323-0220
Sónia FragaUnidade de Investigação em Epidemiologia (EPIUnit), Instituto de Saúde Pública da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal.ORCID 0000-0001-9386-2336
António Albino-TeixeiraRISE-Health, Departamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.ORCID 0000-0003-0097-2953
Roberto Roncon-AlbuquerqueServiço de Medicina Intensiva, Centro Hospitalar e Universitário de São João (CHUSJ), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
Teresa SousaRISE-Health, Departamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.ORCID 0000-0001-7230-5020

Funding

Fundação para a Ciência e Tecnologia https://doi.org/10.54499/UI/BD/150816/2020Fundação para a Ciência e Tecnologia project 519, reference number: 613690173Fundação para a Ciência e Tecnologia PTDC/MEC-CAR/32188/2017Programa Operacional Temático Factores de Competitividade POCI-01-0145-FEDER-032188
6 · The paper itself

Abstract

Annexin A1 (ANXA1) is a proresolving protein regulated by glucocorticoids, the standard care for severe and critical COVID-19 patients. As part of a larger project including hospitalized COVID-19 patients, this study aimed at evaluating ANXA1 and its FPR2 receptor in these patients, focusing on longitudinal profiles and comparison across disease severities and outcomes, and exploring their correlations with inflammation, endotheliitis and other proresolving mediators. Blood was collected in "severe" (

Indexed as

Annexin A1COVID-19 Drug TreatmentDexamethasoneAgedAnti-Inflammatory AgentsCOVID-19CytokinesDocosahexaenoic AcidsEicosapentaenoic AcidFemaleHospitalizationHumansMaleMiddle AgedReceptors, Formyl PeptideReceptors, Lipoxin5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acidAnnexin A1Anti-Inflammatory AgentsANXA1 protein, humanCytokinesDexamethasoneDocosahexaenoic AcidsEicosapentaenoic AcidFPR2 protein, humanReceptors, Formyl PeptideReceptors, Lipoxinresolvin D1annexin A1critical COVID-19dexamethasoneFPR2resolvin E1

Identifiers

PMID42072630
PMCPMC13113340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.